The association between AD pathology and sleep-dependent memory consolidatio

Not Applicable

Recruiting

• Conditions: Alzheimer Disease; Alzheimer's disease; C10.228.140.380.100, C10.574.945.249, F03.615.400.100

• Registration Number: JPRN-jRCT1030230197
• Lead Sponsor: Kuriyama Kenichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Participants who will participate to the AT-Sleep study (jRCT1031220550) are enrolled. Individual selection criteria for healthy volunteers and patients on the Alzheimer's disease (AD) spectrum (mild AD, mild cognitive impairment (MCI), and preclinical AD) are as follows;
Healthy volunteers
1. Normal cognitive function (MMSE score is 28 points or higher)
2. Comprehensive CDR score is 0
3. MRI and PET have already been performed or will be performed in the AT-Sleep study.
4. Polysomnography will be performed in the AT-Sleep study.
5. Participants must fully understand the study and give written consent of their own free will.

Patients with AD spectrum
(Common part)
1. The participants are currently attending our hospital or have a history of research participation, and meet one of the following criteria (A, B, and C.)
2. They fully understand the content of the research and give written consent of their own will.
3. They have a partner who contacts the participant at least once a week and is willing to participate in the study as an informant.
4. They maintain vision, hearing, and writing skills that do not affect cognitive function tests.
5. They have already performed MRI and PET or will perform in the AT-Sleep study.
6. They will undergo polysomnography in the AT-Sleep study.

A. Mild AD
a. Probable AD on NIAAA diagnostic criteria
b. MMSE score is 23 or less
c. 0.5 or 1 on the comprehensive CDR
B. MCI (due to AD)
a. MCI due to AD by NIAAA diagnostic criteria
b. MMSE score is 27 or less
c. Comprehensive CDR score is 0.5 with memory score is 0.5 or 1
C. Preclinical AD
a. Probable AD by NIAAA diagnostic criteria (previously participated in amyloid PET studies, and the amyloid positive finding have been revealed)
b. MMSE core is 28 points or higher
c. Comprehensive CDR score is 0

Exclusion Criteria

Healthy volunteers
1. The participants who have been diagnosed certain neurodegenerative diseases or conditions including AD spectrum, also with multiple cerebral infarctions, normal pressure hydrocephalus, brain tumors, epilepsy, subdural hematoma, multiple sclerosis, or head trauma that results residual damage or abnormal brain structure.
2. They have a focal lesion, such as a cerebral infarction, that could affect infection or cognitive function on MRI.
3. They suffer from cardiac pacemakers, aneurysm clips, cochlear implants, other magnetic or electrically conductive metals, or claustrophobia that causes problems with MRI imaging.
4. They show hypersensitivity to thioflavin derivatives.
5. They have major depression or bipolar disorder defined by DSM-5 within the past year, or have a history of schizophrenia defined by DSM-5 in the past.
6. They have a history of alcohol or drug dependence defined by the DSM-5 within the past 2 years.
7. They have some sleep disorders under treatment.
8. They have a serious systemic illness or unstable conditions.
9. They are judged to be ineligible by the M.D. investigators.
Patients with AD spectrum
1. The participants have a specific neurodegenerative disease other than AD spectrum, including multiple cerebral infarctions, normal pressure hydrocephalus, brain tumor, epilepsy, subdural hematoma, multiple sclerosis, or head injury that has left residual effects or abnormal brain structure.
2. They have a focal lesion, such as a cerebral infarction, that could affect infection or cognitive function on MRI.
3. They suffer from cardiac pacemakers, aneurysm clips, cochlear implants, other magnetic or electrically conductive metals, or claustrophobia that causes problems with MRI imaging.
4. They show hypersensitivity to thioflavin derivatives.
5. They have major depression or bipolar disorder defined by DSM-5 within the past year, or have a history of schizophrenia defined by DSM-5 in the past.
6. They have a history of alcohol or drug dependence defined by the DSM-5 within the past 2 years.
7. They have exhibited psychiatric symptoms, excitability, and behavioral abnormalities to such an extent that adhering to the protocol has become difficult within the past 3 months.
8. They have a serious systemic illness or unstable conditions.
9. They have been admitted to a nursing home or hospital.
10. They are participating in a clinical intervention study or trial at the time of enrollment, or have a history of participation in anti-amyloid therapy trials.
11. They are judged to be ineligible by the M.D. investigators.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sleep-dependent improvement ratios in the PWAT and MDT